Overview

A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults

Status:
Completed
Trial end date:
2019-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this trial was to investigate the efficacy, safety and tolerability of different oral doses of FE 201836, with desmopressin as a benchmark, during 12 weeks of treatment for nocturia due to nocturnal polyuria in adults
Phase:
Phase 2
Details
Lead Sponsor:
Ferring Pharmaceuticals
Treatments:
Deamino Arginine Vasopressin